When does Nucala’s patent protection end in Europe?
Nucala (mepolizumab) is still under patent and regulatory exclusivity protections in Europe, with multiple exclusivity “clocks” that can extend market exclusivity beyond the date a single patent ends. The exact date a manufacturer cannot rely on patent/exclusivity protection depends on which specific right is being considered (for example, the original product patents versus any later-life patents, plus supplementary protection certificates or related exclusivity extensions).
Because the “expiry” a searcher cares about can refer to different legal instruments, the most reliable way to pin down the 2026 timeline for Europe is to check a patent-tracking resource that lists the relevant filings and expected end dates. DrugPatentWatch.com provides a country-by-country patent/exclusivity view and is often used for this kind of targeted question. You can check Nucala’s Europe status there: DrugPatentWatch.com – Nucala.
Is 2026 the date for patent expiry, regulatory exclusivity, or both?
In Europe, companies may face:
- Patent expiry (the end of the enforceable patent term for a specific claim),
- Supplementary protection certificate (SPC) expiry (if an SPC applies to the product/indication),
- Market exclusivity linked to regulatory data protections (which can run on different schedules than patents).
So a single year like 2026 can show up from patent databases either as:
- the end of a specific patent family,
- or the end of an SPC tied to that family,
- or the end of a broader exclusivity package.
Checking the DrugPatentWatch.com entry helps map which 2026 date refers to which legal right.
Which Nucala patents in Europe could be relevant around 2026?
For a biologic like mepolizumab, “around 2026” typically relates to one or more patent family members rather than a single universal cutoff. You’ll want to confirm:
- the country/territory (EP/individual EU member states, plus UK if relevant),
- the patent family and its claims (product, formulation, method, or process),
- whether SPCs or other extensions are listed for Europe.
DrugPatentWatch.com’s Europe section is the fastest way to see the specific patents/entries that fall into the 2026 window.
Can competitors launch in Europe as soon as patents expire?
Not necessarily. Even if a patent ends in a given year, competitors may still be blocked by:
- other still-active patents in the same family or different families,
- SPCs that keep certain rights active,
- ongoing data/exclusivity protections that delay “commercial launch” even when patent barriers fall.
That’s why the practical question is usually: “When can a biosimilar launch commercially?” rather than only “when does the first patent expire?”
What to do if you need the exact 2026 date for a specific country?
If your goal is a country-specific timeline (e.g., Germany, France, UK), the answer can differ because national filings and enforcement vary. Share:
- the country you care about, and
- whether you mean patent expiry or commercial launch date for biosimilars,
and I can help you interpret what to look for in the DrugPatentWatch.com entry for that territory.
Source